[{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"d95c33d6-345e-4cbd-b542-479174b36f3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05797233","created_at":"2023-04-04T16:03:56.139Z","updated_at":"2025-02-25T17:02:29.485Z","phase":"Phase 1","brief_title":"Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies","source_id_and_acronym":"NCT05797233","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MET expression","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2029","study_completion_date":" 12/30/2029","last_update_posted":"2025-02-03"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"701c790f-d71e-4882-8490-72c4deac7a2f","acronym":"BYON3521.001","url":"https://clinicaltrials.gov/study/NCT05323045","created_at":"2022-04-12T14:52:58.036Z","updated_at":"2024-07-02T16:34:37.322Z","phase":"Phase 1","brief_title":"A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521","source_id_and_acronym":"NCT05323045 - BYON3521.001","lead_sponsor":"Byondis B.V.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BYON3521"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"ef2ab7b8-a2e5-4df2-83fe-3e4e96f58f67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04693468","created_at":"2021-01-19T20:49:06.628Z","updated_at":"2024-07-02T16:34:58.952Z","phase":"Phase 1","brief_title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","source_id_and_acronym":"NCT04693468","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • ALK translocation","tags":["ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/03/2025","primary_completion_date":" 09/03/2025","study_txt":" Completion: 09/03/2025","study_completion_date":" 09/03/2025","last_update_posted":"2024-06-04"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"40df6160-751e-485f-9648-832a744ed37a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077099","created_at":"2021-01-18T19:58:00.182Z","updated_at":"2024-07-02T16:35:16.114Z","phase":"Phase 1/2","brief_title":"REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04077099","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e davutamig (REGN5093)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 10/20/2024","study_completion_date":" 10/20/2024","last_update_posted":"2024-03-06"},{"id":"f2a04229-a963-4571-967a-2d4ee1ac84df","acronym":"FLOWERS","url":"https://clinicaltrials.gov/study/NCT05163249","created_at":"2021-12-20T15:53:31.602Z","updated_at":"2024-07-02T16:35:19.919Z","phase":"Phase 2","brief_title":"Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC","source_id_and_acronym":"NCT05163249 - FLOWERS","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-09"},{"id":"30039935-dcb8-4bf7-a489-908bf7235f71","acronym":"LUMINOSITY","url":"https://clinicaltrials.gov/study/NCT03539536","created_at":"2021-01-18T17:26:22.732Z","updated_at":"2024-07-02T16:35:22.832Z","phase":"Phase 2","brief_title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03539536 - LUMINOSITY","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • MET overexpression • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-01-19"},{"id":"8a37d0f9-8abd-490b-aee8-74694dd7e0ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03859752","created_at":"2021-01-18T19:02:32.942Z","updated_at":"2024-07-02T16:35:36.034Z","phase":"Phase 1","brief_title":"TR1801-ADC in Patients With Tumors That Express c-Met","source_id_and_acronym":"NCT03859752","lead_sponsor":"Open Innovation Partners, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TR1801-ADC"],"overall_status":"Suspended","enrollment":" Enrollment 15","initiation":"Initiation: 08/14/2019","start_date":" 08/14/2019","primary_txt":" Primary completion: 07/04/2023","primary_completion_date":" 07/04/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-09-22"},{"id":"10546027-b8fd-4d19-9e12-032fc4a20162","acronym":"","url":"https://clinicaltrials.gov/study/NCT02491840","created_at":"2021-01-18T12:00:42.960Z","updated_at":"2024-07-02T16:35:40.221Z","phase":"","brief_title":"Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study","source_id_and_acronym":"NCT02491840","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" HER-2 • FGFR2","pipe":" | ","alterations":" HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression","tags":["HER-2 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-08-11"},{"id":"1f16af08-2617-4040-87e8-26981325edcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02344810","created_at":"2021-01-18T11:09:02.428Z","updated_at":"2024-07-02T16:35:47.151Z","phase":"Phase 2","brief_title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","source_id_and_acronym":"NCT02344810","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" HER-2 negative • MET amplification • MET expression","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MET amplification • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • AMG 337"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/06/2015","start_date":" 03/06/2015","primary_txt":" Primary completion: 03/06/2015","primary_completion_date":" 03/06/2015","study_txt":"","study_completion_date":"","last_update_posted":"2023-05-25"},{"id":"895f148c-c60c-4d1f-8591-4efa7828dbdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856541","created_at":"2021-01-18T19:01:52.729Z","updated_at":"2024-07-02T16:36:01.650Z","phase":"Phase 1","brief_title":"A Study of SHR-A1403 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT03856541","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SHR-A1403"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/13/2019","start_date":" 02/13/2019","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 05/07/2020","study_completion_date":" 05/07/2020","last_update_posted":"2022-10-28"},{"id":"65fc83f2-6b27-470e-9e3a-58d6f9d2a044","acronym":"INFLUENCE","url":"https://clinicaltrials.gov/study/NCT04574427","created_at":"2021-01-18T21:50:25.975Z","updated_at":"2024-07-02T16:36:02.223Z","phase":"","brief_title":"INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue","source_id_and_acronym":"NCT04574427 - INFLUENCE","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/14/2020","study_completion_date":" 11/14/2020","last_update_posted":"2022-10-19"},{"id":"96636132-56a0-489e-b340-1ee6924108e9","acronym":"EMR200095_001","url":"https://clinicaltrials.gov/study/NCT01014936","created_at":"2021-01-18T03:58:46.209Z","updated_at":"2025-02-25T16:00:11.342Z","phase":"Phase 1","brief_title":"First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01014936 - EMR200095_001","lead_sponsor":"EMD Serono","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 11/30/2009","start_date":" 11/30/2009","primary_txt":" Primary completion: 10/31/2015","primary_completion_date":" 10/31/2015","study_txt":" Completion: 10/31/2015","study_completion_date":" 10/31/2015","last_update_posted":"2022-08-24"},{"id":"e02c420f-a139-4835-ba97-92535de111e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911507","created_at":"2021-01-18T08:37:01.568Z","updated_at":"2025-02-25T15:40:58.472Z","phase":"Phase 1","brief_title":"INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01911507","lead_sponsor":"University of California, Davis","biomarkers":" EGFR • KRAS • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • KRAS wild-type • EGFR L861Q • RAS wild-type • EGFR G719X • MET expression","tags":["EGFR • KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • KRAS wild-type • EGFR L861Q • RAS wild-type • EGFR G719X • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-10-13"},{"id":"c36bb106-df7a-452b-8b1f-240d487bcc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02929290","created_at":"2021-01-18T14:23:12.967Z","updated_at":"2024-07-02T16:36:24.500Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC","source_id_and_acronym":"NCT02929290","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-9016"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-09-13"},{"id":"ef304084-24f3-4d6c-8d3b-2187dc9a6ee6","acronym":"MENTOR","url":"https://clinicaltrials.gov/study/NCT01523340","created_at":"2021-01-17T17:41:01.144Z","updated_at":"2024-07-02T16:36:27.019Z","phase":"","brief_title":"A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response","source_id_and_acronym":"NCT01523340 - MENTOR","lead_sponsor":"Chonnam National University Hospital","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR expression • MET mutation • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR expression • MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2021-08-03"},{"id":"726018f8-a8bb-47b9-b507-183575dc2a24","acronym":"MErCuRIC1","url":"https://clinicaltrials.gov/study/NCT02510001","created_at":"2021-01-18T12:07:19.285Z","updated_at":"2025-02-25T15:33:28.804Z","phase":"Phase 1","brief_title":"MEK and MET Inhibition in Colorectal Cancer","source_id_and_acronym":"NCT02510001 - MErCuRIC1","lead_sponsor":"University of Oxford","biomarkers":" KRAS • MET • NRAS","pipe":" | ","alterations":" MET amplification • MET overexpression • RAS mutation • MET expression","tags":["KRAS • MET • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RAS mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Mektovi (binimetinib) • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2021-07-13"},{"id":"e24fe967-71a4-411d-8e88-e2c4b7a0ed50","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049060","created_at":"2021-01-22T23:52:33.713Z","updated_at":"2024-07-02T16:36:35.705Z","phase":"Phase 1/2","brief_title":"Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin","source_id_and_acronym":"NCT02049060","lead_sponsor":"Armando Santoro, MD","biomarkers":" MET • HGF","pipe":" | ","alterations":" MET expression","tags":["MET • HGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2021-01-22"},{"id":"49a4a0b5-0da7-4007-b016-2998d04ed0a0","acronym":"REFLECT","url":"https://clinicaltrials.gov/study/NCT04031898","created_at":"2021-01-18T19:47:14.893Z","updated_at":"2024-07-02T16:36:36.923Z","phase":"","brief_title":"Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)","source_id_and_acronym":"NCT04031898 - REFLECT","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ALK • TP53 • MET","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation","tags":["HER-2 • ALK • TP53 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • EGFR T790M • MET expression • ALK rearrangement + MET amplification • HER-2 exon 23 mutation"],"overall_status":"Completed","enrollment":" Enrollment 896","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-12-23"},{"id":"d3e4bc84-d494-4f6e-b098-856be6a86d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324479","created_at":"2021-01-18T05:23:36.158Z","updated_at":"2024-07-02T16:36:37.116Z","phase":"Phase 1","brief_title":"Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors","source_id_and_acronym":"NCT01324479","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" EGFR wild-type • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 07/04/2017","primary_completion_date":" 07/04/2017","study_txt":" Completion: 07/04/2017","study_completion_date":" 07/04/2017","last_update_posted":"2020-12-19"}]